肾癌免疫治疗中新兴的新型生物标志物。
Novel emerging biomarkers to immunotherapy in kidney cancer.
作者信息
Ged Yasser, Voss Martin H
机构信息
Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA.
出版信息
Ther Adv Med Oncol. 2021 Nov 25;13:17588359211059367. doi: 10.1177/17588359211059367. eCollection 2021.
Abstract
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ultimately require salvage therapies. An ever deeper understanding of the disease biology mediated by the development of multiple high-throughput molecular omics has led to significant progress in biomarkers discovery. But despite growing insights into the molecular underpinnings of the tumor microenvironment, biomarkers have not been integrated successfully into clinical practice. In this review, we discuss some of the novel emerging predictive biomarkers to ICIs in metastatic renal cell carcinoma.
摘要
近年来，转移性肾细胞癌的治疗有了显著进展，尤其是随着新型免疫检查点抑制剂（ICI）的出现。尽管在群体水平上观察到了显著益处，但治疗结果存在差异，一些患者对基于ICI的治疗方案无反应，最终需要挽救治疗。通过多种高通量分子组学的发展，对疾病生物学有了更深入的理解，这在生物标志物发现方面取得了重大进展。但是，尽管对肿瘤微环境的分子基础有了越来越多的了解，生物标志物尚未成功整合到临床实践中。在本综述中，我们讨论了转移性肾细胞癌中一些新出现的ICI预测生物标志物。
相似文献
1
Novel emerging biomarkers to immunotherapy in kidney cancer.肾癌免疫治疗中新兴的新型生物标志物。
Ther Adv Med Oncol. 2021 Nov 25;13:17588359211059367. doi: 10.1177/17588359211059367. eCollection 2021.
2
Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.肾细胞癌中免疫检查点抑制剂反应和耐药的生物标志物
Cancers (Basel). 2023 Jun 12;15(12):3159. doi: 10.3390/cancers15123159.
3
The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.肠道微生物群在转移性肾细胞癌免疫调节中的作用。
Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122714. doi: 10.1177/17588359221122714. eCollection 2022.
4
Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.多学科免疫治疗为基础的合理组合在肾细胞癌脑转移中获得持久和稳健的疗效。
Int J Mol Sci. 2021 Jun 11;22(12):6290. doi: 10.3390/ijms22126290.
5
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.免疫检查点抑制剂治疗转移性肾细胞癌患者的预后和预测分子生物标志物：系统评价。
Expert Rev Mol Diagn. 2020 Feb;20(2):169-185. doi: 10.1080/14737159.2019.1680286. Epub 2019 Oct 24.
6
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?免疫检查点抑制剂在肿瘤学中的应用与 AKI 的发生：我们处于什么位置？
Front Immunol. 2020 Oct 8;11:574271. doi: 10.3389/fimmu.2020.574271. eCollection 2020.
7
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.免疫相关不良事件作为免疫检查点抑制剂治疗转移性肾细胞癌患者的临床生物标志物。
Oncologist. 2021 Oct;26(10):e1742-e1750. doi: 10.1002/onco.13868. Epub 2021 Jul 8.
8
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.免疫检查点抑制剂在胸部恶性肿瘤中的应用：IASLC 专家小组对现有证据的综述及推荐意见
J Thorac Oncol. 2020 Jun;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006. Epub 2020 Mar 14.
9
State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.未来态势：免疫治疗时代肾细胞癌的转化研究方法
Eur Urol Focus. 2020 Jan 15;6(1):37-40. doi: 10.1016/j.euf.2019.02.014. Epub 2019 Feb 28.
10
Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.新兴的免疫检查点抑制剂治疗头颈部癌症。
Expert Opin Emerg Drugs. 2020 Dec;25(4):501-514. doi: 10.1080/14728214.2020.1852215. Epub 2020 Dec 17.
引用本文的文献
1
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial.晚期肾细胞癌患者中中性粒细胞与嗜酸性粒细胞比值与阿维鲁单抗联合阿昔替尼或舒尼替尼疗效结果的关联：JAVELIN Renal 101试验的事后分析
BMJ Oncol. 2024 Jun 12;3(1):e000181. doi: 10.1136/bmjonc-2023-000181. eCollection 2024.
2
Management of translocation carcinomas of the kidney.肾移行细胞癌的管理
Transl Cancer Res. 2024 Nov 30;13(11):6438-6447. doi: 10.21037/tcr-24-60. Epub 2024 Aug 8.
3
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).接受免疫治疗的晚期肾细胞癌患者的肿瘤微环境分析（Meet-URO 18研究）
Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12.
4
Inflammation and Immunity Gene Expression Patterns and Machine Learning Approaches in Association with Response to Immune-Checkpoint Inhibitors-Based Treatments in Clear-Cell Renal Carcinoma.透明细胞肾细胞癌中与基于免疫检查点抑制剂治疗反应相关的炎症和免疫基因表达模式及机器学习方法
Cancers (Basel). 2023 Nov 29;15(23):5637. doi: 10.3390/cancers15235637.
5
Co-Expression of Multiple Genes in Renal Cell Carcinoma (RCC) and Correlation of High Expression with Favorable Clinical Outcome in RCC Patients.肾细胞癌（RCC）中多个基因的共表达及其在 RCC 患者中与良好临床结局的相关性。
Int J Mol Sci. 2023 Jul 14;24(14):11432. doi: 10.3390/ijms241411432.
6
Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.理解并整合细胞减灭性肾切除术与免疫检查点抑制剂在转移性肾细胞癌治疗中的应用。
Nat Rev Urol. 2023 Nov;20(11):654-668. doi: 10.1038/s41585-023-00776-5. Epub 2023 Jul 3.
7
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.基于纳武利尤单抗免疫治疗反应的晚期肾细胞癌患者原发性肿瘤和转移部位的肿瘤及免疫肿瘤微环境特征：Meet-URO 18研究的初步结果
Cancers (Basel). 2023 Apr 21;15(8):2394. doi: 10.3390/cancers15082394.
8
Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma.肿瘤浸润免疫细胞状态可预测肾细胞癌对免疫检查点抑制剂的成功反应。
Sci Rep. 2022 Nov 27;12(1):20386. doi: 10.1038/s41598-022-24437-6.
9
Dynamic Predictive Models with Visualized Machine Learning for Assessing the Risk of Lung Metastasis in Kidney Cancer Patients.用于评估肾癌患者肺转移风险的可视化机器学习动态预测模型
J Oncol. 2022 Oct 14;2022:5798602. doi: 10.1155/2022/5798602. eCollection 2022.
10
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.预处理身体成分特征与接受免疫检查点阻断治疗的转移性透明细胞肾细胞癌患者临床结局的相关性。
Clin Cancer Res. 2022 Dec 1;28(23):5180-5189. doi: 10.1158/1078-0432.CCR-22-1389.
本文引用的文献
1
Molecular determinants of response to PD-L1 blockade across tumor types.肿瘤类型中 PD-L1 阻断反应的分子决定因素。
Nat Commun. 2021 Jun 25;12(1):3969. doi: 10.1038/s41467-021-24112-w.
2
Alterations and Response to Immunotherapy in Solid Tumors.实体瘤的改变与免疫治疗反应。
Clin Cancer Res. 2021 Jul 15;27(14):4025-4035. doi: 10.1158/1078-0432.CCR-21-0575. Epub 2021 Jun 1.
3
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.高应答率和持久性由接受仑伐替尼和帕博利珠单抗治疗的肾癌患者 HLA 遗传多样性驱动。
Mol Cancer Res. 2021 Sep;19(9):1510-1521. doi: 10.1158/1541-7786.MCR-21-0053. Epub 2021 May 26.
4
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.单细胞测序将ccRCC中的多区域免疫景观和组织驻留T细胞与肿瘤拓扑结构及治疗疗效联系起来。
Cancer Cell. 2021 May 10;39(5):662-677.e6. doi: 10.1016/j.ccell.2021.03.007. Epub 2021 Apr 15.
5
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.在肾癌的疾病进展阶段，免疫功能逐渐受损。
Cancer Cell. 2021 May 10;39(5):632-648.e8. doi: 10.1016/j.ccell.2021.02.013. Epub 2021 Mar 11.
6
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.肿瘤与免疫重编程在晚期肾细胞癌免疫治疗中的作用
Cancer Cell. 2021 May 10;39(5):649-661.e5. doi: 10.1016/j.ccell.2021.02.015. Epub 2021 Mar 11.
7
Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.循环细胞因子与转移性肾细胞癌系统治疗的临床反应相关。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002009.
8
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.NCCN 指南解读：非小细胞肺癌，第 2.2021 版。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):254-266. doi: 10.6004/jnccn.2021.0013.
9
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
10
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
Zotero 插件